Testsealabs® COVID-19 gwajin antigen da FDA ta Philippine ta amince

Taya murna!！“Testsealabs® COVID-19 Antigen Rapid Test” da Testsea kera sun sami Takaddun shaida na FDA a Philippines a ranar 25 ga Afrilu, 2022. Takaddar ta nuna cewa samfuran Testsealabs® COVID-19 Antigen Rapid Test samfuran an yarda dasu don siyarwa a cikin Kasuwar Philippines ta karamar hukuma.

Ana iya amfani da samfuranmu don amfanin ƙwararru da amfanin gida (gwajin kai). Ya dace ga cibiyoyi, daidaikun mutane da iyalai don gano samfuran swab na hanci/nasopharyngeal/oropharyngeal cikin sauri da kuma kan lokaci.

 dalilin shahararsa:

* Babban takamaiman da hankali

* Sakamakon nan take a mintuna 15-20

* Sauƙi don tattara samfuran * Babu kayan aiki da ake buƙata* Ana iya ganin sakamako a fili

* Ya dace da manyan sabbin rawanin* Gano kamuwa da cuta da wuri

Tun bayan barkewar COVID-19, Testsea yana bin tsarin ISO13485 da ISO9001 ingantaccen tsarin gudanarwa tare da bincike, samarwa, sarrafa inganci, kuɗi, tallace-tallacen cikin gida da tallace-tallace na ƙasa da ƙasa da sauransu kuma sun sami takardar shaidar gwajin kai ta CE 1011/1434. a cikin EU, da Therapeutic Products Administration (TGA) takardar shaida a Ostiraliya, Thailand Abinci da Drug Administration (FDA) da wasu sauran takaddun shaida daga kasashe daban-daban, wanda ya nuna ingancin kayayyakin mu aka amince da alaka da cibiyoyin gwamnati. Hakanan, samfuranmu sun sami kyakkyawan suna da tasirin alama daga kasuwannin ketare. Testsea za ta ci gaba da bincike da haɓaka samfuran gwaji cikin sauri na COVID-19 kuma suna ba da gudummawa ga yaƙi da annobar COVID-19 a duniya.